NASDAQ:OPNT - Opiant Pharmaceuticals Stock Price, Price Target & More

$19.43 -0.55 (-2.75 %)
(As of 04/24/2018 12:42 PM ET)
Previous Close$19.98
Today's Range$19.27 - $19.59
52-Week Range$5.00 - $51.90
Volume18,678 shs
Average Volume39,632 shs
Market Capitalization$51.32 million
P/E Ratio6.62
Dividend YieldN/A
Beta-0.6

About Opiant Pharmaceuticals (NASDAQ:OPNT)

Opiant Pharmaceuticals logoOpiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine. Opiant Pharmaceuticals, Inc. has a collaboration agreement with Titan Pharmaceuticals, Inc. to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals, Inc. is a subsidiary of Pelikin Group.

Receive OPNT News and Ratings via Email

Sign-up to receive the latest news and ratings for OPNT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Metal mining
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OPNT
CUSIPN/A
Webwww.opiant.com
Phone310-598-5410

Debt

Debt-to-Equity RatioN/A
Current Ratio1.56%
Quick Ratio1.56%

Price-To-Earnings

Trailing P/E Ratio6.62
Forward P/E Ratio-17.35
P/E GrowthN/A

Sales & Book Value

Annual Sales$18.45 million
Price / Sales2.73
Cash Flow$3.1188 per share
Price / Cash6.23
Book Value$2.14 per share
Price / Book9.08

Profitability

EPS (Most Recent Fiscal Year)$2.94
Net Income$6.58 million
Net Margins-384.42%
Return on Equity-403.59%
Return on Assets-145.89%

Miscellaneous

Employees11
Outstanding Shares2,590,000

How to Become a New Pot Stock Millionaire

Opiant Pharmaceuticals (NASDAQ:OPNT) Frequently Asked Questions

What is Opiant Pharmaceuticals' stock symbol?

Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT."

How were Opiant Pharmaceuticals' earnings last quarter?

Opiant Pharmaceuticals (NASDAQ:OPNT) issued its quarterly earnings data on Monday, December, 4th. The technology company reported ($2.77) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.19) by $1.58. The technology company earned $0.02 million during the quarter. Opiant Pharmaceuticals had a negative net margin of 384.42% and a negative return on equity of 403.59%. View Opiant Pharmaceuticals' Earnings History.

Who are some of Opiant Pharmaceuticals' key competitors?

Who are Opiant Pharmaceuticals' key executives?

Opiant Pharmaceuticals' management team includes the folowing people:
  • Dr. Roger Crystal M.D., CEO, Pres & Director (Age 42)
  • Mr. Kevin Andrew Pollack Esq., J.D., M.B.A., Advisor (Age 48)
  • Mr. David D. O'Toole, CFO, Treasurer & Sec. (Age 59)
  • Dr. Phil Skolnick Ph.D., D.Sc. (hon), Chief Scientific Officer (Age 71)
  • Mr. Quan Vu, VP of Corp. Devel.

Has Opiant Pharmaceuticals been receiving favorable news coverage?

News stories about OPNT stock have been trending somewhat positive on Tuesday, Accern reports. The research group rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Opiant Pharmaceuticals earned a news impact score of 0.19 on Accern's scale. They also gave news stories about the technology company an impact score of 44.28 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of Opiant Pharmaceuticals?

Shares of OPNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Opiant Pharmaceuticals' stock price today?

One share of OPNT stock can currently be purchased for approximately $19.43.

How big of a company is Opiant Pharmaceuticals?

Opiant Pharmaceuticals has a market capitalization of $51.32 million and generates $18.45 million in revenue each year. The technology company earns $6.58 million in net income (profit) each year or $2.94 on an earnings per share basis. Opiant Pharmaceuticals employs 11 workers across the globe.

How can I contact Opiant Pharmaceuticals?

Opiant Pharmaceuticals' mailing address is 201 SANTA MONICA BLVD SUITE 500, SANTA MONICA CA, 90401. The technology company can be reached via phone at 310-598-5410 or via email at [email protected]


MarketBeat Community Rating for Opiant Pharmaceuticals (OPNT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  127 (Vote Outperform)
Underperform Votes:  138 (Vote Underperform)
Total Votes:  265
MarketBeat's community ratings are surveys of what our community members think about Opiant Pharmaceuticals and other stocks. Vote "Outperform" if you believe OPNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPNT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Opiant Pharmaceuticals (NASDAQ:OPNT) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 4/24/2016 forward)

Earnings

Opiant Pharmaceuticals (NASDAQ:OPNT) Earnings History and Estimates Chart

Earnings by Quarter for Opiant Pharmaceuticals (NASDAQ:OPNT)

Opiant Pharmaceuticals (NASDAQ:OPNT) Earnings Estimates

2018 EPS Consensus Estimate: $2.28
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($1.19)($1.19)($1.19)
Q2 20181$4.33$4.33$4.33
Q3 20181($0.36)($0.36)($0.36)
Q4 20181($0.50)($0.50)($0.50)

Opiant Pharmaceuticals (NASDAQ OPNT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/4/2017Q1 2018($1.19)($2.77)$0.02 millionViewN/AView Earnings Details
10/13/2017Q4 2017($0.87)($0.17)$3.77 millionViewN/AView Earnings Details
6/14/2017Q3 2017($0.82)($1.55)$0.02 millionViewN/AView Earnings Details
3/16/2017Q2 2017($0.85)$4.91$13.54 millionViewN/AView Earnings Details
12/16/2016Q1 2017($1.14)($0.30)$0.70 million$1.12 millionViewN/AView Earnings Details
10/31/2016Q4 2016($0.52)$0.10 million$0.31 millionViewN/AView Earnings Details
6/8/2016Q3 2016$0.15$2.61 millionViewN/AView Earnings Details
3/15/2016Q2 2016$1.52$6.86 millionViewN/AView Earnings Details
8/7/2012$0.19$0.21ViewN/AView Earnings Details
5/14/2012$0.20$0.21ViewN/AView Earnings Details
2/7/2012$0.29$0.26ViewN/AView Earnings Details
11/9/2011$0.24$0.24ViewN/AView Earnings Details
8/2/2011$0.15$0.21ViewN/AView Earnings Details
5/9/2011$0.19$0.20ViewN/AView Earnings Details
1/27/2011$0.16$0.23ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Opiant Pharmaceuticals (NASDAQ:OPNT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Opiant Pharmaceuticals (NASDAQ OPNT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 37.92%
Institutional Ownership Percentage: 4.27%
Insider Trading History for Opiant Pharmaceuticals (NASDAQ:OPNT)

Opiant Pharmaceuticals (NASDAQ OPNT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/18/2017Geoffrey WolfMajor ShareholderSell34,938$22.67$792,044.46View SEC Filing  
12/8/2017Geoffrey WolfMajor ShareholderSell2,570$30.40$78,128.00View SEC Filing  
1/17/2017Michael SinclairInsiderBuy3,500$7.01$24,535.00132,720View SEC Filing  
1/17/2017Roger CrystalCEOBuy3,475$6.99$24,290.258,475View SEC Filing  
1/13/2017Kevin PollackInsiderBuy4,820$6.98$33,643.604,820View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Opiant Pharmaceuticals (NASDAQ OPNT) News Headlines

Source:
DateHeadline
Blog Exposure - Opiant Pharma Receives Grant for Development of OPNT003 for Treatment of Opioid OverdoseBlog Exposure - Opiant Pharma Receives Grant for Development of OPNT003 for Treatment of Opioid Overdose
finance.yahoo.com - April 20 at 8:36 AM
Opiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for ...Opiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for ...
globenewswire.com - April 19 at 8:26 AM
BRIEF-Opiant Pharmaceuticals Awarded Grant Of Approximately $7.4 Mln From The National Institutes Of HealthBRIEF-Opiant Pharmaceuticals Awarded Grant Of Approximately $7.4 Mln From The National Institutes Of Health
www.reuters.com - April 19 at 8:26 AM
Opiant awarded $7.4M NIH grant to support OPNT003 development; shares ahead 2% premarketOpiant awarded $7.4M NIH grant to support OPNT003 development; shares ahead 2% premarket
seekingalpha.com - April 18 at 5:37 PM
Opiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid OverdoseOpiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
finance.yahoo.com - April 18 at 8:26 AM
Will Opiant Pharma Solve The Biggest Crisis That The FDA Is Currently Facing?Will Opiant Pharma Solve The Biggest Crisis That The FDA Is Currently Facing?
seekingalpha.com - April 11 at 8:42 AM
ValuEngine Upgrades Opiant Pharmaceuticals (OPNT) to Strong-BuyValuEngine Upgrades Opiant Pharmaceuticals (OPNT) to Strong-Buy
www.americanbankingnews.com - April 9 at 11:35 AM
Opiant Pharmaceuticals (OPNT) Stock Rating Lowered by ValuEngineOpiant Pharmaceuticals (OPNT) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 8 at 11:17 AM
Opiant Pharmaceuticals (OPNT) Lifted to B at TheStreetOpiant Pharmaceuticals (OPNT) Lifted to B at TheStreet
www.americanbankingnews.com - April 6 at 4:46 PM
Opiant Pharmaceuticals (OPNT) Lifted to "Hold" at ValuEngineOpiant Pharmaceuticals (OPNT) Lifted to "Hold" at ValuEngine
www.americanbankingnews.com - April 5 at 1:11 PM
ValuEngine Lowers Opiant Pharmaceuticals (OPNT) to BuyValuEngine Lowers Opiant Pharmaceuticals (OPNT) to Buy
www.americanbankingnews.com - April 4 at 5:19 PM
Zacks: Brokerages Anticipate Opiant Pharmaceuticals Inc (OPNT) to Post -$0.29 Earnings Per ShareZacks: Brokerages Anticipate Opiant Pharmaceuticals Inc (OPNT) to Post -$0.29 Earnings Per Share
www.americanbankingnews.com - April 4 at 1:22 PM
Free Research Report as HubSpot’s Quarterly Earnings Surpassed Analysts’ EstimatesFree Research Report as HubSpot’s Quarterly Earnings Surpassed Analysts’ Estimates
finance.yahoo.com - March 22 at 8:38 AM
Trump says he is working to lower prescription drug pricesTrump says he is working to lower prescription drug prices
finance.yahoo.com - March 20 at 8:40 AM
As U.S. opioid crisis grows, Trump calls for death penalty for dealersAs U.S. opioid crisis grows, Trump calls for death penalty for dealers
finance.yahoo.com - March 20 at 8:40 AM
OPNT: Opiant Developing New Opioid Overdose TreatmentOPNT: Opiant Developing New Opioid Overdose Treatment
finance.yahoo.com - March 19 at 5:10 PM
Opiant Pharmaceuticals, Inc. to Present a Corporate Overview at the Oppenheimer 28th Annual Healthcare ConferenceOpiant Pharmaceuticals, Inc. to Present a Corporate Overview at the Oppenheimer 28th Annual Healthcare Conference
finance.yahoo.com - March 19 at 5:10 PM
Kadmon (KDMN) & Opiant Pharmaceuticals (OPNT) Critical AnalysisKadmon (KDMN) & Opiant Pharmaceuticals (OPNT) Critical Analysis
www.americanbankingnews.com - March 12 at 10:27 AM
Opiant Pharmaceuticals (OPNT) and Syros Pharmaceuticals (SYRS) Critical ReviewOpiant Pharmaceuticals (OPNT) and Syros Pharmaceuticals (SYRS) Critical Review
www.americanbankingnews.com - March 10 at 12:17 PM
Opiant Pharmaceuticals, Inc. Reports Financial Results for August 1, 2017, Through December 31, 2017, and Provides ... - GlobeNewswire (press release)Opiant Pharmaceuticals, Inc. Reports Financial Results for August 1, 2017, Through December 31, 2017, and Provides ... - GlobeNewswire (press release)
globenewswire.com - March 9 at 8:35 AM
Opiant Pharmaceuticals reports 5M resultsOpiant Pharmaceuticals reports 5M results
seekingalpha.com - March 7 at 6:23 PM
Opiant Pharmaceuticals, Inc. Reports Financial Results for August 1, 2017, Through December 31, 2017, and Provides Corporate UpdateOpiant Pharmaceuticals, Inc. Reports Financial Results for August 1, 2017, Through December 31, 2017, and Provides Corporate Update
finance.yahoo.com - March 7 at 6:23 PM
Opiant Pharmaceuticals (OPNT) to Release Earnings on WednesdayOpiant Pharmaceuticals (OPNT) to Release Earnings on Wednesday
www.americanbankingnews.com - March 7 at 1:50 AM
Aegis Awarded Patent for Fast Acting Nasal Spray Opioid Blockers and Pain Medications - GlobeNewswire (press release)Aegis Awarded Patent for Fast Acting Nasal Spray Opioid Blockers and Pain Medications - GlobeNewswire (press release)
globenewswire.com - February 22 at 8:30 AM
Aegis Awarded Patent for Fast Acting Nasal Spray Opioid Blockers and Pain MedicationsAegis Awarded Patent for Fast Acting Nasal Spray Opioid Blockers and Pain Medications
finance.yahoo.com - February 22 at 8:30 AM
Q2 2018 EPS Estimates for Opiant Pharmaceuticals Inc Lifted by Analyst (OPNT)Q2 2018 EPS Estimates for Opiant Pharmaceuticals Inc Lifted by Analyst (OPNT)
www.americanbankingnews.com - February 15 at 10:18 AM
OPNT: Developing Longer-Acting Opioid Overdose TreatmentOPNT: Developing Longer-Acting Opioid Overdose Treatment
finance.yahoo.com - February 13 at 3:50 PM
Opnet Technologies, Inc. (OPNT) Reports ~$11.7M in Royalty & Milestone Payments Related to 2017 Sales of NARCANOpnet Technologies, Inc. (OPNT) Reports ~$11.7M in Royalty & Milestone Payments Related to 2017 Sales of NARCAN
www.streetinsider.com - February 9 at 9:48 AM
Opiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments Related to 2017 ... - GlobeNewswire (press release)Opiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments Related to 2017 ... - GlobeNewswire (press release)
globenewswire.com - February 8 at 8:18 AM
Opiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments Related to 2017 Sales of NARCAN® Nasal Spray for Opioid OverdoseOpiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments Related to 2017 Sales of NARCAN® Nasal Spray for Opioid Overdose
finance.yahoo.com - February 8 at 8:18 AM
Opiant Pharmaceuticals Receives Approximately $5.3 Million of Cash from Exercise of Outstanding Warrants - GlobeNewswire (press release)Opiant Pharmaceuticals Receives Approximately $5.3 Million of Cash from Exercise of Outstanding Warrants - GlobeNewswire (press release)
globenewswire.com - January 2 at 5:35 PM
Opiant Pharmaceuticals Receives Approximately $5.3 Million of Cash from Exercise of Outstanding WarrantsOpiant Pharmaceuticals Receives Approximately $5.3 Million of Cash from Exercise of Outstanding Warrants
finance.yahoo.com - January 2 at 5:35 PM
Insider Q&A: Narcan exec talks merits of spray for overdosesInsider Q&A: Narcan exec talks merits of spray for overdoses
marketbeat.com - December 31 at 8:25 AM
Critical Contrast: BioMarin Pharmaceutical (BMRN) vs. Opiant Pharmaceuticals (OPNT)Critical Contrast: BioMarin Pharmaceutical (BMRN) vs. Opiant Pharmaceuticals (OPNT)
www.americanbankingnews.com - December 27 at 10:00 AM
ValuEngine Lowers Opiant Pharmaceuticals (OPNT) to SellValuEngine Lowers Opiant Pharmaceuticals (OPNT) to Sell
www.americanbankingnews.com - December 23 at 4:14 PM
BioMarin Pharmaceutical (BMRN) versus Opiant Pharmaceuticals (OPNT) Head-To-Head SurveyBioMarin Pharmaceutical (BMRN) versus Opiant Pharmaceuticals (OPNT) Head-To-Head Survey
www.americanbankingnews.com - December 22 at 11:22 PM
Zacks Investment Research Brokers Raise Earnings Estimates for Opiant Pharmaceuticals Inc (OPNT)Zacks Investment Research Brokers Raise Earnings Estimates for Opiant Pharmaceuticals Inc (OPNT)
www.americanbankingnews.com - December 22 at 1:26 PM
FY2018 Earnings Forecast for Opiant Pharmaceuticals Inc Issued By Zacks Investment Research (OPNT)FY2018 Earnings Forecast for Opiant Pharmaceuticals Inc Issued By Zacks Investment Research (OPNT)
www.americanbankingnews.com - December 21 at 5:50 PM
Geoffrey Wolf Sells 34,938 Shares of Opiant Pharmaceuticals Inc (OPNT) StockGeoffrey Wolf Sells 34,938 Shares of Opiant Pharmaceuticals Inc (OPNT) Stock
www.americanbankingnews.com - December 21 at 2:18 PM
OPNT: Will Begin Receiving 90% of NARCAN® Nasal Spray Royalties in 1Q18OPNT: Will Begin Receiving 90% of NARCAN® Nasal Spray Royalties in 1Q18
finance.yahoo.com - December 20 at 4:40 PM
Opiant Pharmaceuticals Announces Significant Financial Developments Related to NARCAN® Nasal Spray for Opioid OverdoseOpiant Pharmaceuticals Announces Significant Financial Developments Related to NARCAN® Nasal Spray for Opioid Overdose
finance.yahoo.com - December 20 at 10:18 AM
OPNT: News Surrounding Opioid Crisis Shows Need Still High for NARCAN® Nasal SprayOPNT: News Surrounding Opioid Crisis Shows Need Still High for NARCAN® Nasal Spray
finance.yahoo.com - December 19 at 4:39 PM
Opiant Pharmaceuticals (Nasdaq: OPNT) to Ring The Nasdaq Stock Market Opening Bell - NasdaqOpiant Pharmaceuticals (Nasdaq: OPNT) to Ring The Nasdaq Stock Market Opening Bell - Nasdaq
www.nasdaq.com - December 19 at 10:17 AM
Opiant Pharmaceuticals to Ring The Nasdaq Opening Bell on December 20, 2017Opiant Pharmaceuticals to Ring The Nasdaq Opening Bell on December 20, 2017
finance.yahoo.com - December 19 at 10:16 AM
Opiant Pharmaceuticals (Nasdaq: OPNT) to Ring The Nasdaq Stock Market Opening BellOpiant Pharmaceuticals (Nasdaq: OPNT) to Ring The Nasdaq Stock Market Opening Bell
finance.yahoo.com - December 19 at 10:16 AM
Opiant Pharmaceuticals Announces Publication of New Pre-Clinical Data Supporting Potential of OPNT005 as a Heroin VaccineOpiant Pharmaceuticals Announces Publication of New Pre-Clinical Data Supporting Potential of OPNT005 as a Heroin Vaccine
finance.yahoo.com - December 18 at 10:37 AM
Opiant Pharmaceuticals (OPNT) Downgraded by TheStreetOpiant Pharmaceuticals (OPNT) Downgraded by TheStreet
www.americanbankingnews.com - December 14 at 12:34 AM
Opiant Pharmaceuticals Inc (OPNT) Major Shareholder Geoffrey Wolf Sells 2,570 SharesOpiant Pharmaceuticals Inc (OPNT) Major Shareholder Geoffrey Wolf Sells 2,570 Shares
www.americanbankingnews.com - December 12 at 6:06 PM
Opiant Pharmaceuticals, Inc. :OPNT-US: Earnings Analysis: Q1, 2018 By the Numbers : December 7, 2017Opiant Pharmaceuticals, Inc. :OPNT-US: Earnings Analysis: Q1, 2018 By the Numbers : December 7, 2017
finance.yahoo.com - December 7 at 10:34 AM
KalVista Pharmaceuticals (KALV) versus Opiant Pharmaceuticals (OPNT) Head to Head SurveyKalVista Pharmaceuticals (KALV) versus Opiant Pharmaceuticals (OPNT) Head to Head Survey
www.americanbankingnews.com - December 5 at 1:28 PM

SEC Filings

Opiant Pharmaceuticals (NASDAQ:OPNT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Opiant Pharmaceuticals (NASDAQ:OPNT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Opiant Pharmaceuticals (NASDAQ OPNT) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.